The connections between C75 and obesity drug-target pathways

Francis P. Kuhajda, Leslie E. Landree, Gabriele V. Ronnett

Research output: Contribution to journalArticle

Abstract

Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

Original languageEnglish (US)
Pages (from-to)541-544
Number of pages4
JournalTrends in Pharmacological Sciences
Volume26
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Fatty Acid Synthases
Fatty Acids
Obesity
Carnitine
Anorexia
Human Development
Medical problems
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Weight Loss
Oxidation
Molecules
Therapeutics
Inhibition (Psychology)

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

The connections between C75 and obesity drug-target pathways. / Kuhajda, Francis P.; Landree, Leslie E.; Ronnett, Gabriele V.

In: Trends in Pharmacological Sciences, Vol. 26, No. 11, 11.2005, p. 541-544.

Research output: Contribution to journalArticle

Kuhajda, Francis P. ; Landree, Leslie E. ; Ronnett, Gabriele V. / The connections between C75 and obesity drug-target pathways. In: Trends in Pharmacological Sciences. 2005 ; Vol. 26, No. 11. pp. 541-544.
@article{f3a39f867a3b46e29d3dfa2ed1c99542,
title = "The connections between C75 and obesity drug-target pathways",
abstract = "Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.",
author = "Kuhajda, {Francis P.} and Landree, {Leslie E.} and Ronnett, {Gabriele V.}",
year = "2005",
month = "11",
doi = "10.1016/j.tips.2005.09.002",
language = "English (US)",
volume = "26",
pages = "541--544",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - The connections between C75 and obesity drug-target pathways

AU - Kuhajda, Francis P.

AU - Landree, Leslie E.

AU - Ronnett, Gabriele V.

PY - 2005/11

Y1 - 2005/11

N2 - Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

AB - Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

UR - http://www.scopus.com/inward/record.url?scp=27144469291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144469291&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2005.09.002

DO - 10.1016/j.tips.2005.09.002

M3 - Article

C2 - 16169094

AN - SCOPUS:27144469291

VL - 26

SP - 541

EP - 544

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 11

ER -